Drugs · Entity Annotation Prototype (beta)

4articles mentioning drugs

13drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Palonosetron ×

Palonosetron

This drug is selected. Its supporting articles are shown below.

Palonosetron4

Articles mentioning Palonosetron

4 articles · page 1 of 1

P05 Safe adoption of palonosetron into paediatric oncology unit

bmjpo · abstract · 2026-04-09 · 9 matching annotations

99.3%

Palonosetron chemotherapy Medicine safety steps

…stem which included a warning for 5 days following a stat dose. Palonosetron can not be prescribed as stat standalone item. It can only be p…

Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial

bmjopen · abstract · 2026-04-03 · 2 matching annotations

98.0%

megestrol acetate palonosetron oxaliplatin-induced Oxaliplatin oxaliplatin-based dexamethasone DEX gastric or gastro-oesophageal junction cancer

… junction cancer and (3) support the potential incorporation of megestrol acetate into standard antiemetic medications.Ethics and dissemination T…

Extended physicochemical stability of ready-to-administer fosnetupitant/palonosetron infusion solutions and admixtures with dexamethasone injection

ejhpharm · abstract · 2026-06-23 · 1 matching annotations

86.9%

Akynzeo PAL FNET

…ant (FNET) and palonosetron (PAL). Prior to administration, the Akynzeo concentrate (20 mL vial) is diluted with 30 mL 0.9% sodium chlo…

4CPS-045 Optimisation of antiemetic therapy based on individual response in colorectal cancer patients treated with moderately emetogenic chemotherapy

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

80.1%

XELOX Cetuximab Irinotecan Bevacizumab palonosetron netupitant aflibercept colorectal cancer Oncohaematology Pharmaceutical Care Clinic moderately emetogenic chemotherapy

…uctured pharmacist-led follow-up. The excellent tolerability of XELOX, with no need for rescue therapy, suggests this subgroup could …